Navigation Links
EntreMed Reports First Quarter 2008 Financial Results
Date:5/2/2008

ROCKVILLE, Md., May 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three months ended March 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Company reported a net loss for the first quarter of approximately ($8.3 million), or ($0.10) per share, compared with a net loss of ($7.7 million), or ($0.09) per share, for the same period last year. The Company did not report any revenues for the first quarter 2008. As of March 31, 2008, the Company had cash and short-term investments of approximately $44 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented on the first quarter results, "The Company's first quarter 2008 financial results were in line with our projections. During the first quarter, the Company made the decision to invest behind Panzem(R) for rheumatoid arthritis rather than oncology, given 2ME2's mechanisms of action, safety profile and substantially larger market opportunity. Patients currently enrolled in Panzem(R) oncology trials will continue to receive treatment, and we expect to realize cost savings from the discontinuation of the program beginning in the second half of this year. We further expect operational expenses to remain at similar levels through the second quarter as we phase out the Panzem(R) NCD oncology program and advance the clinical development of ENMD-2076. Consistent with the past couple of years, we anticipate recording royalty revenue beginning in the third quarter and decreasing our research and development expenses slightly once the open Panzem(R) oncology trials conclude."

James S. Burns, EntreMed President and CEO commented, "Going forward, we will focus our resources on the development of our three oncology product candidates, MKC-1, ENMD-1198 and ENMD-2076, as well as early clinical development of Panzem(R) in rheumatoid arthritis. We continue to operate in line with our financial guidance for 2008. We believe that the full effect of winding down the Panzem(R) oncology program and our priority oncology program focus will begin to positively impact our financial statement by 3Q08. In addition, we are actively seeking opportunities to offset or share development costs with pharmaceutical partners in order to advance some of our programs into later stages of development. We remain on track with our guidance and we have the financial resources to fund current and planned activities into 2009."

Mr. James S. Burns will present a corporate overview at the Rodman & Renshaw 5th Annual Healthcare Conference being held May 19-20, 2008. Mr. Burns is scheduled to present on Monday, May 19, 2008 at 10:25 a.m. local time. The presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

March 31,

2008 2007

Total revenues $ 0 $ 0

Research and development $ 6,187,203 $ 6,398,696

General and administrative $ 1,982,994 $ 1,831,326

Net Loss $ (8,346,456) $ (7,673,586)

Net loss per share attributable to

common shareholders (basic and diluted) $ (0.10) $ (0.09)

Weighted average number of

shares outstanding (basic and diluted) 84,898,912 84,015,999

Cash and Short-term Investments $ 43,643,620 $ 46,233,046

CONTACT:

Ginny Dunn

EntreMed, Inc.

Associate Director

Corporate Communications &

Investor Relations

(240) 864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
2. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
3. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
4. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
7. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
8. EntreMed to Present at the Bio 2007 Investor Forum
9. EntreMed Receives Deloitte Technology Fast 50 Award
10. Cepheid Reports Record Revenue of $44.8 Million
11. Cephalon Reports Strong First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... DC (PRWEB) , ... February ... ... Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop ... The partnership will recruit top students from U.S. universities who will draw ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical Therapy Association ... CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the country are ... action, learn more about their chosen field and network with their colleagues. As ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The series ... behaviors and create new habits. The workshops cover a broad range of topics, ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, a ... beginning of the latest charity campaign in their community enrichment program. Art Expression ... this worthy cause are currently being accepted at: http://artexpressioninc.org/ . , Art ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology: